Sanofi has appointed Mike Quigley, a former executive at Gilead and Bristol Myers Squibb, as the French pharma’s next chief scientific officer, Endpoints News has learned.
Quigley will replace Frank Nestle, who left Sanofi in May to lead Deerfield Management’s drug discovery arm. Quigley will start in his new role of CSO and global head of research on Sept. 30, according to an internal memo obtained by Endpoints.
Quigley, who has a PhD in immunology from Duke University, has worked in the biopharma industry since 2009. He left Gilead as its senior vice president of research biology in 2021 to join Therini Bio, a startup that raised a $36 million Series A last year. His LinkedIn profile also lists him as co-founder and CEO of a stealth biotech startup in San Francisco.
Houman Ashrafian, Sanofi’s global head of R&D, announced the news on Monday in an email to employees, saying Quigley’s hiring completes his leadership team and “will be key to developing Sanofi as an immunology powerhouse.”
“In his new role, Mike’s mission will be to maximize our probability of success through optimal collaborations across our organization and beyond, bringing best-in-class innovation as well as developing and sourcing new industry-leading talent with a commitment to diversity,” Ashrafian wrote.